Envoy Medical reported minimal revenue as it remains a development-stage medical technology company. The company is focused on the clinical and regulatory progress of its fully implanted Acclaim cochlear implant, finishing the quarter with significantly improved liquidity following substantial equity financing.
Key Highlights
- Submitted the first of four modular PMA application sections to the FDA for the Breakthrough Device-designated Acclaim cochlear implant.
- Reported 12-month clinical data for Stage 1 participants showing a mean CNC word recognition score of 53.2%, a 38.0 percentage point improvement over pre-implantation baselines.
- Cash reserves increased to $19.7 million from $3.7 million at year-end 2025, primarily driven by $27.5 million in net proceeds from financing activities including a $30.0 million equity and warrant offering.